Preferred Label : Anti-SIRPalpha Monoclonal Antibody BYON4228;
NCIt synonyms : Pan-allelic Antagonistic SIRPa Monoclonal Antibody BYON4228; Anti-SIRP-alpha Monoclonal Antibody BYON4228; Anti-SIRPa Monoclonal Antibody BYON4228;
NCIt definition : A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory
protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing
and antineoplastic activities. Upon administration, anti-SIRPalpha monoclonal antibody
BYON4228 targets and binds to the two allelic variants of SIRPa v1 and v2 expressed
on innate immune cells, including monocytes, macrophages, dendritic cells (DCs), and
neutrophils, thereby blocking the interaction between SIRPa and its ligand cluster
of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated
signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis and the
CD47/SIRPa-mediated suppression of the innate immune response. This induces pro-phagocytic
signaling and the specific phagocytosis of tumor cells, and restores immune responses
mediated by myeloid cells in the tumor microenvironment (TME). SIRPa, an innate immune
checkpoint receptor expressed primarily on myeloid cells and neurons that is also
known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative
regulation of phagocytosis, mast cell activation and DC activation. CD47, also known
as integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed
on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface
of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa,
leads to the inhibition of phagocytosis and the suppression of innate immunity, which
allows cancer cells to proliferate.;
Molecule name : BYON 4228; BYON-4228;
NCI Metathesaurus CUI : CL1907118;
Origin ID : C200309;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
